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Abstract
Objective: Neonatal seizures are the most frequent type of neurological emergency 
in newborn infants, often being a consequence of prolonged perinatal asphyxia. 
Phenobarbital is currently the most widely used antiseizure drug for treatment of neona-
tal seizures, but fails to stop them in ~50% of cases. In a neonatal hypoxia-only model 
based on 11-day-old (P11) rats, the NKCC1 inhibitor bumetanide was reported to poten-
tiate the antiseizure activity of phenobarbital, whereas it was ineffective in a human trial 
in neonates. The aim of this study was to evaluate the effect of clinically relevant doses 
of bumetanide as add-on to phenobarbital on neonatal seizures in a noninvasive model 
of birth asphyxia in P11 rats, designed for better translation to the human term neonate.
Methods: Intermittent asphyxia was induced for 30 minutes by exposing the rat pups 
to three 7 + 3–minute cycles of 9% and 5% O2 at constant 20% CO2. Drug treatments 
were administered intraperitoneally either before or immediately after asphyxia.
Results: All untreated rat pups had seizures within 10 minutes after termination of 
asphyxia. Phenobarbital significantly blocked seizures when applied before asphyxia 
at 30 mg/kg but not 15 mg/kg. Administration of phenobarbital after asphyxia was in-
effective, whereas midazolam (0.3 or 1 mg/kg) exerted significant antiseizure effects 
when administered before or after asphyxia. In general, focal seizures were more 
resistant to treatment than generalized convulsive seizures. Bumetanide (0.3 mg/kg) 
alone or in combination with phenobarbital (15 or 30 mg/kg) exerted no significant 
effect on seizure occurrence.
Significance: The data demonstrate that bumetanide does not increase the efficacy 
of phenobarbital in a model of birth asphyxia, which is consistent with the negative 
data of the recent human trial. The translational data obtained with the novel rat 
model of birth asphyxia indicate that it is a useful tool to evaluate novel treatments 
for neonatal seizures.
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1 |  INTRODUCTION
Neonatal seizures are the most common neurological emer-
gency in the neonatal period, occurring in 1-5 per 1000 live 
births.1 Prolonged perinatal asphyxia is a major cause of 
seizures and hypoxic-ischemic encephalopathy in the neo-
natal population.1–3 Notwithstanding its potential toxicity in 
neonates,4 the antiseizure drug (ASD) phenobarbital is still 
the first-line therapy. However, despite the use of high doses 
of phenobarbital (10-40 mg/kg), seizures are controlled in 
fewer than one-half of the neonates.2,5 Variable efficacy 
(ranging from minimal to 100%) has been reported for the 
benzodiazepine, midazolam, as a second-line medication.2 
Neonates with continued seizures have a poor prognosis, 
including significant mortality and, in survivors, serious 
sequelae such as mental retardation, a wide range of neu-
ropsychiatric disorders, motor deficits, and epilepsy.2 Thus, 
improving the treatment of neonatal seizures is an urgent 
medical need.5,6
Phenobarbital potentiates the effect of the inhibitory neu-
rotransmitter γ-aminobutyric acid (GABA) by enhancing the 
hyperpolarizing chloride (Cl−) ion-mediated current across 
GABAA receptors in target neurons.
7 The transmembrane 
electrochemical Cl− gradient of neurons is set by the inter-
action of Cl−-permeable channels and by secondary-active 
ion-transporters, of which the Cl− importer NKCC1 and the 
Cl− exporter KCC2 are the major ones.8 Several studies have 
shown that KCC2 expression in the human neonate is high,8 
which results in the low intracellular Cl− concentration re-
quired for the hyperpolarizing action of GABA. However, 
following neuronal trauma, downregulation KCC2 and up-
regulation of NKCC1 may occur. As a result, Cl− inbound 
transport exceeds the outbound transport, so that intracellular 
Cl− levels are high, thus resulting in a reversed Cl− gradient. 
This results in a change in the functionality of GABA in dam-
aged neurons, which becomes depolarizing/excitatory rather 
than hyperpolarizing/inhibitory, possibly explaining the poor 
efficacy of phenobarbital and other ASDs (eg, benzodiaze-
pines such as midazolam) that act via GABAergic mecha-
nisms in neonates.9 However, whether and to what extent this 
mechanistic scheme is valid for the brain of the asphyxiated 
human neonate is not known.
Based on preclinical studies, the potent loop diuretic, 
bumetanide, has been proposed to be useful in suppressing 
seizures following perinatal brain injury, because it may re-
store GABAergic inhibition by blocking neuronal NKCC1 
in the brain, thereby increasing the efficacy of phenobar-
bital and other positive modulators of GABAA receptors to 
suppress neonatal seizures.10–12 This prompted two clinical 
trials in newborn babies with seizures to examine the effi-
cacy of bumetanide, administered together with phenobarbi-
tal (US Food and Drug Administration Investigational New 
Drug No. 101690: http://clini caltr ials.gov/ct2/show/NCT00 
830531; EU FP7 NEMO: http://www.nemo-europe.com/). 
The European trial with bumetanide (0.05-0.3 mg/kg) as ad-
junct to phenobarbital (10 mg/kg) for treatment of neonatal 
seizures was stopped early because of serious adverse reac-
tions (ototoxicity) and no evidence for seizure reduction.13 
The US trial was started in 2009, but the results have not been 
published as yet.
The negative outcome of the European trial raises ques-
tions about the translational value of the preclinical models 
that have been used to evaluate the effect of bumetanide and 
phenobarbital combinations. For instance, in the study of 
Cleary et al,14 10-day-old (P10) rat pups were exposed to hy-
poxia for 15 minutes, which induced acute seizures in 95% 
of vehicle controls during the hypoxia. When phenobarbital 
(15  mg/kg intraperitoneal [ip]) and/or bumetanide (0.15 or 
0.3 mg/kg ip) were administered prior to seizure induction, 
phenobarbital or bumetanide alone did not significantly re-
duce seizure incidence, whereas a reduction by 75%-85% 
was obtained by combining either dose of bumetanide with 
phenobarbital.14 The authors concluded that “these data pro-
vide preclinical support for clinical trials of bumetanide in 
human neonates at risk for hypoxic encephalopathy and sei-
zures.” However, in human asphyxiated neonates, seizures 
occur mainly during the recovery period following perinatal 
asphyxia,2,3 not during the hypoxic episode associated with 
complicated birth. Asphyxia is, by definition, a combination 
of hypoxia and hypercapnia, and recent work has shown the 
elevation in brain CO2 levels has robust brain-sparing ef-
fects,15 whereas the recovery to normocapnia (and the asso-
ciated rise in pH) promotes seizures in the model used in the 
present study.16
Key Points
• Neonatal seizures are the most common neuro-
logical emergency in the neonatal period and only 
poorly respond to antiseizure drugs
• Neonates with continued seizures have a poor 
prognosis, so improving the treatment of neonatal 
seizures is an urgent medical need
• In rodents, bumetanide was reported to potentiate 
the antiseizure activity of phenobarbital, but was 
ineffective in a clinical trial in neonates
• We used a novel rat model of birth asphyxia and 
found that phenobarbital and midazolam partially 
suppressed the seizures, whereas bumetanide was 
ineffective
• These data indicate that this model is a useful tool 
to evaluate novel treatments for neonatal seizures
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The aim of this study was to evaluate whether the anti-
seizure effect of bumetanide/phenobarbital combinations 
reported by Cleary et al14 for a rat hypoxia-only model of 
neonatal seizures is also observed in a novel asphyxia model 
of such seizures. For this goal, we used a model of birth as-
phyxia seizures recently described by us in P11-12 rats,16 
which correspond to term human babies.17–19 In contrast to 
hypoxia-only models such as the one used by Cleary et al,14 
seizures in this asphyxia model develop after the insult,16 
which closely parallels the situation in human neonates. For 
characterizing the pharmacology of the asphyxia-induced 
seizures in rat pups, we administered phenobarbital and the 
potent benzodiazepine, midazolam, either before or after 
the period of asphyxia. Furthermore, we tested bumetanide 
alone and in combination with phenobarbital, using the doses 
and administration schedule described in the study of Cleary 
et al.14
2 |  MATERIALS AND METHODS
2.1 | Animals
Breeding pairs of Wistar Han (Crl:WI[Han] outbred) rats 
were obtained from Charles River. The animals were kept 
under controlled environmental conditions (22-24°C; 50%-
60% humidity; 12-hour light/dark cycle; light on at 6:00 am) 
with free access to standard laboratory chow (Altromin 1324 
standard diet; Altromin) and tap water. Male and female off-
spring were used at P11 (where P0 refers to the day of birth). 
Each litter was separated into pups that served as controls and 
pups that were used for drug treatment as described below. 
The numbers of breeder pairs and litters used for the present 
study are shown in Table S1.
Experiments were performed in Hannover, Germany, 
according to the EU council directive 2010/63/EU and the 
German Law on Animal Protection (Tierschutzgesetz). 
Ethical approval for the study was granted by an ethical 
committee (according to §15 of the Tierschutzgesetz) and 
the governmental agency (Lower Saxony State Office for 
Consumer Protection and Food Safety) responsible for ap-
proval of animal experiments in Lower Saxony (reference 
number for this project: 17/2604). All efforts were made to 
minimize both the suffering and the number of animals. A 
total of 173 rat pups were used for the present experiments. 
All animal experiments of this study are reported in accor-
dance with ARRIVE guidelines.20
2.2 | Asphyxia model of neonatal seizures
Details of this novel model are reported elsewhere.15,16 For 
the present experiments, the intermittent asphyxia protocol 
was slightly modified, because the previously used protocol 
with alternating 5-minute periods of 9% O2/20% CO2 and 5% 
O2/20% CO2 with a total duration of 30 minutes was associated 
with high mortality in the present experiments, most likely 
attributable to subtle substrain differences in the Wistar out-
bred rats used in the present and previous work (cited above). 
The protocol illustrated in Figure 1 was used. In short, the rat 
pups were placed in exposure chambers (one per chamber), 
with a constant temperature of 35.5°C, 15 min prior to expo-
sure to asphyxia; under these conditions the animals’ rectal 
temperature stabilizes to 36-37 °C.16 Intermittent asphyxia 
was induced for 30 minutes by exposing the rat pups to three 
cycles of 7 minutes 9% O2 and 3 minutes 5% O2 at a constant 
elevated level of CO2 (20% of atmospheric pressure), as il-
lustrated in Figure 1. Gases were humified and delivered at 
a flow rate of 3000 mL/min into two exposure chambers; the 
size of each chamber was 12  ×  12.2  ×  12.3  cm, resulting 
in a chamber volume of 1800 cm3. When possible, control 
and drug-treated pups were performed in parallel, using one 
chamber per animal. After the asphyxia protocol, animals 
were promptly re-exposed to room air. Animals were closely 
observed during and for at least 10 minutes after asphyxia 
by two investigators, who were blinded to the treatments. 
Furthermore, the animals’ behavior was video-monitored 
by two cameras, one from the side and one from above, to 
allow offline post hoc analyses of behavioral alterations. In 
the absence of drug treatment, all animals developed seizures 
within 10 minutes after the end of asphyxia (see Results). The 
type and severity of these seizures were scored by a modified 
Racine scale21 as described in Table 1. Furthermore, parox-
ysmal behavioral symptoms and automatisms that could not 
be rated by this scale were noted. Mortality associated with 
asphyxia was recorded. For sham asphyxia, all experimental 
procedures were identical, except that the pups were exposed 
to room air in the chambers used for asphyxia.
In some experiments, the cortical electroencephalogram 
(EEG) was recorded before, during and after asphyxia. 
Epidural EEG screw electrodes were implanted into the skull 
above the motor cortex 1 day before asphyxia under anesthe-
sia with isoflurane. Stereotactic coordinates for the cortical 
electrode in millimeters from bregma22 were anteroposterior 
(AP), +1.5; mediolateral (ML), +1.5. A reference screw elec-
trode was implanted at AP, +1.5; ML, −1.5; and a ground-
ing screw at AP, −3.8; ML, +2.0. The EEG was recorded in 
freely moving rat pups with simultaneous video recording, 
using the parameters and EEG/video equipment described in 
detail previously.23
2.3 | Drug treatment
As shown in Figure 1, three drugs were evaluated: pheno-
barbital (15 or 30 mg/kg ip), midazolam (0.3 or 1 mg/kg 
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ip), and bumetanide (0.3  mg/kg ip). The latter drug was 
administered either alone or in combination with pheno-
barbital (15 mg/kg or 30 mg/kg ip). Doses of phenobarbital 
and bumetanide were those used by Cleary et al.14 These 
doses are in the range used clinically in human neonates.3 
In experiments, in which phenobarbital and bumetanide 
were administered before asphyxia, we used the pretreat-
ment times described by Cleary et al14 as illustrated in 
Figure 1. Midazolam was injected immediately before or 
after asphyxia. Furthermore, in an additional experiment, 
phenobarbital (30 mg/kg ip) was injected 15 minutes be-
fore or immediately after asphyxia. Because phenobarbital 
(30 mg/kg) was not effective when administered immedi-
ately after asphyxia (see Results), we examined whether 
bumetanide (0.3  mg/kg) administered together with phe-
nobarbital (30 mg/kg) after asphyxia increases the efficacy 
of phenobarbital. Together with each drug experiment, a 
group of untreated rat pups was tested in parallel in a treat-
ment-blind manner. Rat pups were randomly assigned to 
the different groups. For midazolam, which was dissolved 
in sterile water for injection, concurrent controls received 
the vehicle. This also allowed evaluating whether vehicle 
injection induced any differences compared to untreated 
controls. Maternal separation was equally long in test and 
control animals.
2.4 | Drug analysis in plasma and brain
Some drug-treated animals were killed 10 minutes after as-
phyxia (after the seizure surveillance period) for determin-
ing drug concentrations in plasma and brain. Phenobarbital, 
bumetanide, and midazolam were extracted from plasma 
and brain and determined by high-performance liquid chro-
matography with ultraviolet detection as described previ-
ously.23,24 Detection limit for bumetanide in the brain tissue 
was 0.009 µg/g.
2.5 | Drugs
Phenobarbital (used as sodium salt; Serva) was dissolved in 
sterile water. For experiments in which bumetanide (Sigma) 
was administered before asphyxia, it was dissolved in a 
F I G U R E  1  Schematic presentation of the experimental protocol used for the present experiments. Intermittent asphyxia was induced for 30 
minutes by exposing the rat pups to three cycles of 7 minutes to 9% O2 and for 3 minutes to 5% O2 at a constant elevated level of CO2 (20% of 
atmospheric pressure). After asphyxia, the average time of onset and duration of seizure activity and the average duration of observation of the rat 
pups are indicated. For details, see Ala-Kurikka et al.16 Bum, bumetanide; MDZ, midazolam; PB, phenobarbital
924 |   JOHNE Et al





Alterations in cortical 
EEG Comments
Clinical correlates in 
neonates
I Mouth or facial 
clonus






of whole body 
(rapid isolated 
jerks)
No change observed Nonconvulsive (limbic?) Epileptic spasms 
(may result in head 
nodding) and/or rapid 
isolated myoclonic 
jerks (random single 
contractions)
III Uni- or bilateral 
repetitive clonic 
seizures of limbs 
(without loss of 
righting)
Epileptic activity (see 
Figure 2)
Generalized convulsive (motor) Clonic seizures 
(repetitive jerking, 
unifocal or multifocal); 
seizure type best 
recognized clinically
IV Uni- or bilateral 
repetitive clonic 
seizures of limbs 
and tonic seizures of 
fore- or hindlimbs 
(without loss of 
righting)
Epileptic activity (see 
Figure 2)
Generalized convulsive (motor); rearing 
(as in the original Racine scale) is not 




V Repetitive clonic 
seizures of limbs 
and tonic seizures of 
fore- or hindlimbs 
(± wild running) 
with loss of righting 
(falling)
Epileptic activity (see 
Figure 2)
Generalized convulsive (motor) Tonic stiffening; 
decerebrate posturing; 
usually focal, unilateral 
or bilateral asymmetric; 











or bending of body 
or limbs resembling 
infantile spasms
No change observed Subtle seizures are the 
most common seizure 
type in both preterm 




eye deviation, eye 
opening), oral 
phenomena (see stage 










No change observed May occur before, in-between, or after 
seizures; not clear whether these behaviors 
represent nonconvulsive limbic seizures
Motor automatisms
Note.: For clinically obvious seizures, seizure type and severity were graded by a modified Racine scale. The different seizure stages do not have to occur in sequence 
(from lowest to highest stage), but, presumably because of involvement of different brain structures, may occur in a mixed manner. Seizures originating presumably 
from the limbic system (eg, mouth clonus, stereotypies) are likely to occur before seizures originating from forebrain cortical areas (eg, clonic) or the brain stem 
(tonic seizures). None of the clinically obvious seizures or other paroxysmal behavioral symptoms shown in the table occurred after sham asphyxia (see text). For the 
clinically obvious seizures and other paroxysmal behavioral symptoms occurring after asphyxia in rat pups, clinical correlates in neonates are shown for comparison 
(based on the current International League Against Epilepsy classification recently reported by Pressler et al1).
Abbreviation: EEG, electroencephalogram.
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vehicle containing 5% ethanol, 5% Solutol HS 15 (a nonionic 
solubilizer consisting of ethoxylated 12-hydroxystearic acid; 
BASF), and 90% distilled water. For experiments in which 
bumetanide was administered together with phenobarbital 
after asphyxia, we dissolved this drug together with phe-
nobarbital in an aqueous 10% solution of hydroxypropyl-ß-
cyclodextrin (HPßCD; Kleptose, Roquette-Pharma), which 
contained 2.25% glucose. Preliminary experiments with so-
lutions of bumetanide in ethanol/Solutol vs HPßCD did not 
indicate any differences in drug pharmacokinetics, includ-
ing brain distribution. The reason for avoiding the ethanol/
Solutol solution shortly after asphyxia was the potential an-
tiseizure activity of ethanol administered shortly before onset 
of seizures.23 Midazolam was used as commercial aqueous 
solution of its hydrochloride (midazolam-hameln), which 
was diluted by sterile water. All drugs were injected ip; in-
jection volume was 10 mL/kg, except for combined treatment 
with bumetanide and phenobarbital before asphyxia, for 
which injection volume was 3 mL/kg per drug, and treatment 
with midazolam, for which injection volume was 1.7 mL/kg.
2.6 | Statistics
In all experiments, rat pups from a given litter were randomly 
assigned to the drug and vehicle groups and experiments were 
performed in a blinded fashion. Statistical analyses were per-
formed using GraphPad Prism 8.0 software. Either parametric or 
nonparametric tests were used for statistical evaluation, depend-
ing on data distribution. For comparison of two groups, either 
Student t test, Mann-Whitney U test, or Wilcoxon signed rank 
test was used, depending on whether data were paired. In case of 
more than two groups, we used analysis of variance (ANOVA) 
with post hoc testing and correction for multiple comparisons. 
Depending on data distribution, either the ANOVA F test, fol-
lowed post hoc by Dunnett multiple comparisons test, or the 
Kruskal-Wallis test followed post hoc by Dunn multiple com-
parisons test was used. For comparison of frequencies in a 2 × 2 
table, Barnard unconditional test25 was used, because this test 
preserves the significance level and generally is more power-
ful than Fisher exact test for moderate to small samples.26 All 
tests were used two-sided; P < .05 was considered significant. 
G*Power Data Analysis27 was used to calculate the necessary 
sample size for a specified power of 80%.
3 |  RESULTS
3.1 | Behavioral alterations during and after 
asphyxia in P11 rats
Exposing the rat pups to the asphyxia protocol shown in 
Figure 1 did not produce any obvious behavioral effects, apart 
from brief agitation on initiation of the exposure. Seizures 
were never seen during the asphyxia. However, following es-
tablishment of normocapnic conditions after asphyxia, all rat 
pups exhibited clinically obvious seizures (stage I-V) within 
0.5-7.4  minutes (mean = 2.1  minutes). These seizures oc-
curred repeatedly over a period of 0.5-8.97 minutes (mean = 
3.7 minutes) postasphyxia, after which the animals resumed 
normal behavior. In agreement with previous findings16 and 
as shown in Table 2, the predominant seizure type was gener-
alized convulsive (stage III-V) seizures, particularly general-
ized tonic-clonic (stage V) seizures. The average latency to 
convulsive stage III-V seizures was 2.2 minutes (range = 1.0-
3.88 minutes). Individual group values for seizure latencies 
are shown in Table S2. Representative examples of seizures 
are shown in Video S1.
In addition, several other paroxysmal symptoms, which 
were not observed following sham asphyxia, were deter-
mined in the pups, including fragmentary body movements 
(limb posturing, swimming, pedaling) that are also seen 
following asphyxia in human neonates (Table 1; Video S1). 
Similarly, stereotyped behaviors, described as motor automa-
tisms during human neonatal seizures, were determined in the 
rat pups (Table 1; Video S1). When these other paroxysmal 
symptoms and automatisms were included in calculation of 
latency to first symptom after termination of asphyxia, a la-
tency period of 0.33-3.5 minutes (mean = 1.31 minutes) was 
obtained. In this respect, it is important to note that subtle sei-
zures are the most common seizure type in both preterm and 
term babies, with manifestations such as ocular phenomena 
(staring, blinking, eye deviation, eye opening), oral phenom-
ena, fragmentary body movements (limb posturing, swim-
ming, pedaling), and autonomic phenomena.1 In the rat pups 
of the present asphyxia model, distinct types of such subtle 
seizures were observed in 30%-60% of the animals (Table 2).
Again, in agreement with previous work,16 the typical 
generalized convulsive (stage III-V) seizures recorded after 
asphyxia were paralleled by paroxysmal, epileptic activity 
in the cortical EEG (Table 1). Examples of such EEG alter-
ations are illustrated in Figure  2B-D. The clinical seizures 
observed during EEG recording are illustrated above each 
EEG trace. In apparent contrast to generalized convulsive 
stage III-V seizures, stage I/II limbic seizures and the other 
paroxysmal symptoms and automatisms observed in the rat 
pups after asphyxia were not paralleled by cortical EEG alter-
ations (Table 1), indicating that they arose from subcortical 
or paleocortical areas such as the limbic system. During as-
phyxia, the EEG amplitude was suppressed compared to the 
preasphyxia baseline (Figure 2A).
The average number of clinically obvious (stage I-V) sei-
zures following termination of asphyxia was 2.44 (range = 1-5) 
per animal. Seizures typically progressed through several stages 
(see examples in Figure 2). Average seizure severity (using the 
highest rated seizure per animal) was 3.83 (range = 1-5).
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When data were calculated separately for male (n = 14) 
and female pups (n = 9), no significant differences in av-
erage latency to first seizure (1.5 ± 0.2 minutes vs 1.8 ± 
0.4; P = .4662), the average period over which seizures 
were observed (3.8 ± 0.7 minutes vs 3.0 ± 0.7 minutes; 
P = .4504), and the average number of seizures (2.7 ± 
0.3 vs 2.9 ± 0.4 seizures/pup; P = .6888) were obtained. 
Furthermore, as shown in Figure S1, all untreated controls 
and all vehicle-injected controls of both sexes exhibited 
100% seizure incidence.
Rat pups that were injected with vehicle (sterile water) 
before or after asphyxia appeared to exhibit more convul-
sive (stage III-V) seizures than untreated controls (Table 2; 
Figure 3). This, however, was a random effect that was not 
observed when analyzing additional groups of untreated P11 
rat pups (data not shown).
Mortality associated with asphyxia was low (Table 2) and 
not affected by litter size. Rat pups typically died during the 
last 5 minutes of asphyxia. The surviving rat pups exhibited 
no obvious alterations in body weight gain or general health 
status in subsequent weeks (not illustrated).
In view of the relatively short latencies between the 
end of asphyxia and onset of seizures, which is a poten-
tial problem for drug efficacy testing when drugs are ad-
ministered after asphyxia (see below), we evaluated several 
modifications of the protocol illustrated in Figure 1. When 
the duration of intermittent asphyxia was increased from 
30  minutes to 40 or 60  minutes, the average latency to 
convulsive seizures increased by only ~10% but mortality 
largely increased to 30% and 50%, respectively. We there-
fore decided to use the protocol illustrated in Figure 1 for 
drug experiments.
F I G U R E  2  Representative examples of cortical electroencephalographic (EEG) recordings in postnatal day 11 rat pups. A, EEG before onset 
of asphyxia, during asphyxia, and in the recovery period after asphyxia. Note EEG suppression during asphyxia and the seizures (indicated by 
asterisk) occurring during the recovery phase. These seizures are shown in more detail in D below. In B-D, clinical seizures observed during EEG 
recording are illustrated above each EEG trace, using the colors indicated in the seizure stage legend in the figure. B, Paroxysmal EEG alterations 
during evolution of postasphyxic seizures from stage I (nonconvulsive) to stage III (convulsive). Note that nonconvulsive seizure activity was 
observed before and after convulsive seizure activity. C, Paroxysmal EEG alterations during evolution of postasphyxic seizures from stage III to 
stage IV. Note that nonconvulsive seizure activity was observed after convulsive seizure activity. D, Paroxysmal EEG alterations during evolution 
of postasphyxic seizures from stage III to stage V. Note that nonconvulsive seizure activity was observed after convulsive seizure activity
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3.2 | Effects of drug treatment
Treatment with 15  mg/kg phenobarbital 15  minutes be-
fore onset of asphyxia did not significantly reduce postas-
phyxic seizure incidence when compared to a concurrent 
untreated control group (Figure 3A). However, when com-
pared to all untreated controls used in this study, a sig-
nificant (50%) decrease in clinically obvious (stage I-V) 
seizures and a 38% decrease in all seizures were observed 
in the phenobarbital-treated pups (Table  2). When the 
dose of phenobarbital was increased to 30  mg/kg, a sig-
nificant 75% decrease in seizure incidence was obtained 
(Figure  3A, Table  2). The generalized convulsive (stage 
III-V) seizures were completely prevented by this dose, 
whereas nonconvulsive stage I-II seizures were resistant 
to treatment.
Bumetanide 0.3 mg/kg administered alone 15 minutes be-
fore onset of asphyxia did not significantly reduce seizures 
F I G U R E  3  Drug effects on seizure incidence in the postnatal day 11 rat asphyxia model of neonatal seizures. Drugs or vehicle were 
administered either 15 or 30 minutes before onset of asphyxia or immediately after termination of asphyxia as shown in Figure 1. All types of 
seizures, including clinically obvious (stage I-V) seizures as well as other paroxysmal behavioral alterations and automatisms, were included in 
calculation of seizure incidence (see Tables 1 and 2); the highest seizure stage observed in each animal was used for the average values shown 
here. Seizure incidence is illustrated as percent of animals with seizures versus animals without seizures. Group size is indicated below the bars. 
Significant differences in seizure incidence from concurrent controls are indicated by asterisks (P < .05); actual P values are shown in Table 2. 
A, Effect of phenobarbital (PB). The drug was administered either at 15 and 30 mg/kg intraperitoneally (ip) 15 minutes before onset of asphyxia 
or at 30 mg/kg after termination of asphyxia. B, Effect of bumetanide (Bum) 0.3 mg/kg ip alone or in combination with 15 mg/kg PB on seizure 
incidence. Bum was injected 15 minutes and PB 30 minutes before onset of asphyxia. C, Effect of midazolam (MDZ). The drug was administered 
ip either at 1 mg/kg 15 minutes before onset of asphyxia or at 0.3 or 1 mg/kg immediately after termination of asphyxia. The MDZ vehicle was also 
either injected before and after asphyxia; because seizure incidence was 100% in both vehicle groups, they are shown together in one bar (n = 28)
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of any stage developing after asphyxia (Figure 3B; Table 2). 
Furthermore, a combination of phenobarbital (15  mg/kg; 
30  minutes before asphyxia) and bumetanide (0.3  mg/kg; 
15  minutes before asphyxia) did not exert any significant 
effect on seizures of any stage. Instead, combination with 
bumetanide tended to decrease the antiseizure efficacy of phe-
nobarbital compared to treatment with phenobarbital alone 
(P = .071). Furthermore, in the group treated with bumetanide 
alone, 35% of the pups died compared to 15% in untreated 
controls, which, however, was not significant (P = .1187).
Obviously, ASDs can be administered to the neonate in 
the neonatal intensive care unit only after parturition when re-
covery from asphyxia starts, not during or before. Therefore, 
we performed experiments in which drugs were injected 
immediately after the termination of asphyxia (Figure  1). 
With phenobarbital 30 mg/kg, no significant antiseizure ef-
fect was observed. This can be explained by the short latent 
period (about 2 minutes; see above) between termination of 
asphyxia and onset of postasphyxic seizures, because phe-
nobarbital penetrates into the brain and cerebrospinal fluid 
F I G U R E  4  Plasma and brain levels of drugs in postnatal day 11 rat pups, determined 10 minutes after termination of asphyxia. As shown 
in Figure 1, drugs were administered either before or after asphyxia, which is indicated below the bars. Data are shown as mean ± SEM; as 
shown below the bars in A, group size is 8 (phenobarbital [PB] 15 mg/kg before asphyxia), 3 (PB 15 mg/kg + bumetanide [Bum] 0.3 mg/kg 
before asphyxia), 8 (PB 30 mg/kg before asphyxia), 13 (PB 30 mg/kg + Bum 0.3 mg/kg after asphyxia), 3 (Bum 0.3 mg/kg before asphyxia), 5 
(midazolam [MDZ] 1 mg/kg before asphyxia), 8 (MDZ 0.3 mg/kg after asphyxia), and 4 (MDZ 1 mg/kg after asphyxia), respectively. Significant 
differences in PB levels and brain:plasma ratio determined for 30 mg/kg administered either before or after asphyxia are indicated by asterisks 
(P < .05), whereas significant differences in Bum levels and brain:plasma ratio determined for 0.3 mg/kg administered either before or after 
asphyxia are indicated by hash signs (P < .05). With respect to these differences, please note that PB 30 mg/kg was either injected 15 minutes 
before asphyxia or immediately after asphyxia, and plasma and brain levels were determined in both experiments 10 minutes after asphyxia; this 
explains the lower brain levels when PB was administered after asphyxia, because PB penetrates into the brain only slowly.29,31 In contrast, when 
the same treatment protocol was used for Bum 0.3 mg/kg, Bum brain levels were higher when determined 10 versus 55 minutes after its injection, 
indicating rapid penetration into the brain but also rapid elimination as reported previously in adult rats.42 A, Plasma levels of PB, Bum, and of 
MDZ. B, Brain levels. The average brain level of Bum is shown above the respective bars. C, Brain:plasma ratio. The average brain:plasma ratio of 
Bum is shown above the respective bars
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relatively slowly.28,29 When bumetanide (0.3 mg/kg) was in-
jected together with phenobarbital (30 mg/kg) shortly after 
asphyxia, again no significant antiseizure effect was deter-
mined (Figure  3B); however, the incidence of stereotypies 
was increased significantly (Table 2).
In contrast, midazolam (1 mg/kg) potently suppressed sei-
zures when administered before or after asphyxia (Table 2; 
Figure  3C). When administered before asphyxia, the anti-
seizure effect of midazolam was similar to that of high-dose 
phenobarbital in that a significant 80% decrease in seizure 
incidence was observed. Again, the generalized convulsive 
(stage III-V) seizures were completely prevented by this dose 
of midazolam, whereas nonconvulsive stage I-II seizures 
were resistant to treatment. When midazolam (1 mg/kg) was 
injected after asphyxia, seizure incidence was reduced by 
53%. Benzodiazepines are known to penetrate into the brain 
within seconds after parental injection,30 thus explaining the 
beneficial efficacy compared to phenobarbital when injected 
after asphyxia in our model.
Based on the significant antiseizure effect of midazolam 
(1  mg/kg) injected after asphyxia, we performed an addi-
tional experiment in which we decreased the dosage of mid-
azolam to 0.3 mg/kg. As shown in Table 2 and Figure 3C, 
midazolam significantly reduced the incidence of seizures by 
33%, thus demonstrating that the effect of midazolam was 
dose-dependent. However, the generalized convulsive (stage 
III-V) seizures were completely prevented by this dose of 
midazolam, whereas nonconvulsive stage I-II seizures were 
resistant to treatment.
In none of the drug experiments were obvious differences 
between male and female pups observed (Figure S1). At the 
lower dose of phenobarbital, male rat pups appeared to be 
more responsive to the anticonvulsant effect of this drug than 
female pups; however, the low sample size per sex excluded 
any meaningful quantification. Only for the experiments with 
the higher dose of midazolam (1 mg/kg) after asphyxia was 
group size per sex large enough for determining potential sex 
differences. The number of midazolam responders was simi-
lar in male (6/9) and female (5/10) rat pups in this experiment 
(Figure S1C).
In addition to determining the effects of drugs on seizure 
incidence, we also evaluated whether drug treatment exerted 
an effect on seizure latency. As shown in Table S2, except 
for midazolam (1 mg/kg after asphyxia), none of the treat-
ments significantly altered the latency to seizure onset after 
asphyxia. Midazolam increased the latency to nonconvulsive 
seizures 2.4-fold compared to seizure latency determined 
after injection of the midazolam vehicle.
All drug experiments described above were performed 
with ip administration, whereas the clinical route of treatment 
of neonatal seizures is typically intravenous (iv).3 Preliminary 
experiments in P11 rat pups showed that iv administration 
via the tail veins is easily possible before asphyxia. However, 
immediately after asphyxia, the tail veins were constricted, 
most likely as a consequence of circulatory centralization, so 
that iv injection was successful in only ~20% of the pups. We 
therefore decided to skip the iv route in the present study.
3.3 | Drug levels in plasma and brain
When phenobarbital (15 or 30 mg/kg ip) was administered 
15 minutes before onset of asphyxia and plasma and brain 
drug levels were determined 10  minutes after termination 
of asphyxia, that is, shortly after the postasphyxic seizures, 
brain levels of phenobarbital were only moderately lower 
than those determined in plasma, with average brain:plasma 
ratios of 0.71 (15 mg/kg) and 0.77 (30 mg/kg), respectively 
(Figure  4). Combined treatment with bumetanide did not 
significantly affect plasma or brain levels of phenobarbital 
(15 mg/kg) or its plasma:brain ratio (Figure 4). When phe-
nobarbital (30  mg/kg) was administered immediately after 
asphyxia and plasma and brain levels were determined 
10 minutes later, brain levels and the brain:plasma ratio of 
phenobarbital were significantly lower compared to the 
values determined 55  minutes after drug administration 
(Figure 4B,C). This can be readily explained by the relatively 
slow brain penetration of this drug, which reaches maximal 
brain levels only at ≥2 hours after iv administration in rats.31
In contrast to phenobarbital, as reported previously for 
adult rodents,24,32,33 bumetanide only poorly penetrated into 
the brain, resulting in an average brain:plasma ratio of only 
0.036, when bumetanide (0.3 mg/kg) was injected 15 minutes 
before asphyxia (Figure 4C). Significantly higher brain lev-
els were determined when the same dose of bumetanide was 
injected immediately after asphyxia (ie, about 10 minutes be-
fore determining plasma and brain levels; Figure 4B), thus 
indicating a very rapid (but incomplete) penetration of this 
drug into the brain. Phenobarbital did not alter the plasma or 
brain levels of bumetanide (Figure 4). Thus, as shown pre-
viously,14 the blood-brain barrier (BBB) of neonatal rats is 
not more penetrable by bumetanide than the BBB of adults, 
so that brain bumetanide levels (~0.01-0.03 µg/mL = 0.028-
0.084 µM) were far below those needed to inhibit NKCC1, 
particularly when considering the extensive brain tissue bind-
ing of bumetanide (cf Brandt et al33).
It is also important to note that in rodents, bumetanide is 
much more rapidly eliminated than phenobarbital. The aver-
age elimination half-life of bumetanide in adult rats is only 
~10 minutes24 compared to 9-20 hours for phenobarbital34; 
the interdrug difference in elimination half-life may be even 
higher in neonatal rats.
Midazolam (1 mg/kg) achieved about the same plasma and 
brain concentrations, irrespective of whether the drug was ad-
ministered before or after asphyxia (Figure 4). Brain:plasma 
ratio was about 2.2-2.4, indicating brain accumulation of this 
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lipophilic drug. At the lower dose of midazolam (0.3  mg/
kg), administered after asphyxia, plasma and brain levels 
were about one-third of those determined at 1 mg/kg, but the 
brain:plasma ratio was the same (Figure 4).
4 |  DISCUSSION
The present study illustrates the antiseizure efficacy of clini-
cally used ASDs in a recently described novel rat model of 
birth asphyxia,16 whereas the NKCC1 inhibitor bumetanide 
is ineffective. To our knowledge, this is the first rodent model 
of postasphyxic neonatal seizures that allows testing of drugs 
after asphyxia, because, as in human neonates, seizures 
occur during establishment of normocapnic conditions (see 
Introduction). As shown here, administration of midazolam 
after asphyxia blocked seizures in about 50% of the rat pups, 
whereas phenobarbital was not effective, most likely as a 
consequence of its slow brain penetration. When high doses 
of phenobarbital or midazolam were administered shortly 
before asphyxia, both drugs blocked postasphyxic convul-
sive seizures, whereas nonconvulsive seizures were resist-
ant. Bumetanide was not capable of potentiating the effect of 
phenobarbital, independently of whether it was administered 
before or after asphyxia. The present translational data ob-
tained with the novel rat model of birth asphyxia indicate that 
this model is a useful tool to evaluate novel treatments for 
neonatal seizures.
As discussed in detail recently,15,16 the present model of 
asphyxia-induced neonatal seizures in P11 rat pups paral-
lels human birth asphyxia but differs in several important 
aspects from the pure-hypoxia models that are widely used 
in neonatal research.35 As pointed out in the Introduction, 
in human neonates, the most common cause of postnatal 
seizures is prolonged perinatal asphyxia, exposing the fetus 
or newborn to hypoxia and hypercapnia with significant ac-
idosis, which suppresses neuronal activity during asphyxia. 
This is also observed in the present model,16 as exempli-
fied by the decreased EEG amplitude during asphyxia. As 
in human neonates, seizures are observed during recovery 
from asphyxia, and these seizures are paralleled by a rise 
in blood and brain pH.15,16,36 The postasphyxic seizures 
observed in the present model cover the whole spectrum 
of neonatal seizures that occur in human newborns.1 
Thus, the present model closes an important gap (see, eg, 
Lombroso37) between the laboratory and the clinic. In line 
with this conclusion, the pharmacology of the postasphyxic 
seizures in P11 rat pups seems to be more translationally 
relevant than previous drug studies in other models of neo-
natal seizures, in which the seizures were induced by hy-
poxia or the excitotoxic convulsant kainate.14,38–40
The negative outcome of the present experiment with 
bumetanide (0.3 mg/kg ip) as adjunct to phenobarbital (15 
or 30 mg/kg ip) for treatment of postasphyxic neonatal sei-
zures is in line with the negative outcome of the European 
multicenter NEMO trial reported by Pressler et al.13 Thus, 
the present asphyxia model correctly predicts the failure of 
bumetanide to increase the antiseizure efficacy of phenobar-
bital in human neonates. This is in contrast to the study per-
formed by Cleary et al14 in a noninvasive rat hypoxia model, 
in which bumetanide (administered before hypoxia) poten-
tiated the antiseizure efficacy of phenobarbital with exactly 
the same doses and pretreatment times that have been used 
here. Interestingly, in a mouse model of ischemia-induced 
neonatal seizures in mice, bumetanide (0.1-0.2 mg/kg) also 
failed to potentiate the action of phenobarbital (25  mg/kg) 
at P7 and P12, and significantly blunted the effect of pheno-
barbital at P10.41 Thus, when using an etiologically relevant 
rodent model of neonatal seizures, bumetanide, administered 
at clinically relevant doses, is not an effective adjunct of 
phenobarbital.
This is not surprising, because bumetanide only poorly 
penetrates into the brain and is highly bound to brain lipids 
and proteins, so that it does not reach NKCC1-inhibitory 
brain levels at clinically relevant doses.33 Thus, it is difficult 
to explain by which mechanism(s) clinically used doses of 
bumetanide (0.1-0.5 mg/kg ip) potentiated the antiseizure ef-
fect of phenobarbital14 or suppressed seizures when adminis-
tered alone40 in hypoxia models of neonatal seizures. Effects 
of bumetanide on apically expressed NKCC1 in the BBB, 
off-target effects (not mediated by NKCC1), and systemic ef-
fects of bumetanide have been discussed in this context.9,12,33 
At a much higher dose (10 mg/kg ip), bumetanide enhanced 
the antiseizure effect of phenobarbital in an invasive neona-
tal cerebral hypoxia-ischemia rat model, but this effect was 
lost at 2.5 mg/kg bumetanide.39 At 10 mg/kg, unbound brain 
levels of bumetanide reach the concentration range (0.1-
0.3 µM) needed to inhibit NKCC1.33 It will be interesting to 
see whether the more BBB-permeable bumetanide prodrugs 
examined in our previous work42 are more efficient than the 
parent compound in the present model.
In contrast to the inability of bumetanide to potentiate the 
antiseizure effect of phenobarbital (15  mg/kg) in the pres-
ent model, the higher, still clinically relevant dose of phe-
nobarbital (30 mg/kg) was quite effective to reduce seizure 
incidence when applied before, but not after, the asphyxia 
exposure. Similarly, the potent benzodiazepine midazolam 
suppressed the seizures, which is in line with its use as a 
second-line ASD for neonatal seizures.5 Interestingly, midaz-
olam was effective in suppressing the seizures when injected 
either before or after asphyxia (before seizure onset), thus 
substantiating its rapid brain penetration. It may be argued 
that the effective dose (1 mg/kg) of midazolam used here was 
considerably higher than the average dose (0.15-0.3 mg/kg) 
used clinically.43 However, as a result of different administra-
tion routes (ip here and iv clinically) and species differences 
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in drug elimination and body surface area,44 the average 
plasma levels 10  minutes after ip administration of midaz-
olam (1 mg/kg) in rat pups (~0.18 µg/mL) were in the range 
(~0.14-0.2 µg/mL) determined 10 minutes after iv adminis-
tration of 0.1-0.2 mg/kg in pediatric patients.45,46 At a lower, 
clinically relevant dose of midazolam (0.3 mg/kg), which was 
administered after asphyxia, seizures were only prevented in 
~30% of the rat pups. However, the severe generalized con-
vulsive (stage III-V) seizures were completely prevented by 
this dose of midazolam.
Despite the efficacy of midazolam and phenobarbital to 
block convulsive neonatal seizures, both drugs were inef-
fective to suppress nonconvulsive seizures, that is, the most 
frequent type of neonatal seizures in humans.5 Furthermore, 
both drugs may induce apoptotic neuronal death in specific 
regions of the immature brain4 and increase neonatal sei-
zure-associated neuronal injury,47 so novel treatments for 
neonatal seizures are urgently needed.48 The present model 
of asphyxia-induced neonatal seizures may help to identify 
such novel therapies.
Some of the properties of the present model of birth as-
phyxia have immediate implications for the technical design 
of pharmacological experiments. The onset of epileptiform 
activity is fast, starting around 2  minutes after the end of 
asphyxia. Although this is a clear advantage over noninva-
sive hypoxia-only models, in which seizures occur during 
hypoxia,16 the short latency between asphyxia and onset of 
seizures in the present model complicates drug testing for 
pharmacokinetic reasons. This limits the range of ASDs that 
can be tested for antiseizure efficacy after asphyxia to drugs 
such as midazolam, which penetrates extremely fast into the 
brain,30 whereas drugs such as phenobarbital do not reach 
sufficiently high levels at their brain targets within the time 
frame necessary. This is illustrated by the different efficacy 
of high-dose phenobarbital administered before versus after 
asphyxia in the present study. Bumetanide did not potenti-
ate phenobarbital when being administered as adjunct to 
phenobarbital after asphyxia. A study design with drug ad-
ministration after asphyxia would better represent the clinical 
treatment of human birth asphyxia.
Interestingly, in the experiments of Kang et al,41 in which 
phenobarbital (25 mg/kg ip) was given 1 hour after onset of 
permanent unilateral carotid-ligation to produce acute isch-
emic seizures on P7, P10, and P12 CD1 mice, phenobarbi-
tal was effective as an antiseizure agent at P10 and P12, but 
bumetanide as an adjunct failed to improve the efficacy of 
phenobarbital. Thus, the outcome of our study design with 
administration of phenobarbital and bumetanide before and 
after asphyxia is similar to the results of Kang et al41 with ad-
ministration of these drugs after onset of an ischemic insult.
In human neonates, ASDs are typically administered iv, 
whereas we used ip administration here, which has pharma-
cokinetic limitations such as lower bioavailability and slower 
onset of pharmacological effects compared to the iv route. 
As described in Results, we tried to inject drugs iv before 
and after asphyxia in rat pups, but the yield of successful iv 
drug injections after asphyxia was too low to allow using this 
route routinely in large groups of pups. This was a result of 
circulatory centralization after asphyxia, leading to tail vein 
constriction, which is inherent in all valid noninvasive mod-
els of asphyxia. Chronic implantation of iv catheters before 
onset of asphyxia and some of the iv injection techniques 
that have been described previously in neonatal rodents49–52 
are feasible alternatives for future experiments, although all 
these techniques are exacting procedures.
Increased neuronal NKCC1 expression has been impli-
cated in neonatal seizures in humans6,9–12 (although data sup-
porting this hypothesis are missing), but the role of NKCC1 
upregulation, if any, in the present model is not yet known. 
Cleary et al14 reported that the expression of NKCC1 pro-
tein transiently increased in cortex and hippocampus after 
hypoxic seizures in P10 rat pups. In apparent contrast, no sig-
nificant changes were detected in NKCC1 expression in the 
mouse model of ischemia-induced neonatal seizures used by 
Kang et al.41 We plan to quantify NKCC1 brain expression in 
our model as well, using novel specific antibodies together 
with proper NKCC1 knockout controls for the visualization 
of endogenous NKCC1 in distinct cell types and their subcel-
lular compartments. In this respect, it is important to note that 
(1) most of the NKCC1 in brain tissue is expressed in glial 
cells, oligodendrocytes, astroglia, and microglia but not in 
neurons; and (2) the lack of specific NKCC1 antibodies has 
thus far complicated the interpretation of immunochemical 
studies on the subcellular distribution of NKCC1.8,9 These 
technical issues seem to explain most of the discrepancies in 
NKCC1 expression in the pertinent literature.
In conclusion, as outlined in detail recently,15,16 the non-in-
vasive rat model used here is the first physiologically-valid 
rodent model of birth asphyxia with neonatal seizures trig-
gered after the insult. The present pharmacological data in-
dicate that this model is a useful tool to evaluate current as 
well as novel treatments for neonatal seizures. Furthermore, 
our model may be used to study the detrimental long-term 
consequences of neonatal asphyxia and seizures and whether 
it is possible to prevent or minimize such consequences by 
pharmacological intervention after asphyxia.
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